CORE Biomedicine raises $21M Series A for lineage-based cancer therapies
What's the deal? CORE Biomedicine has raised $21 million in a Series A round co-led by UTokyo Innovation PlatformDealroom has a profile for this one. Try Dealroom → and Elikon VentureDealroom has a profile for this one. Try Dealroom →. InnoPinnacle FundDealroom has a profile for this one. Try Dealroom →, Mitsubishi UFJ CapitalDealroom has a profile for this one. Try Dealroom →, and Suzhou Capital GroupDealroom has a profile for this one. Try Dealroom → also participated.
What's the endgame? The company develops lineage-based precision oncology therapies, targeting the core biological pathways that define cancer cell identity. It says the approach extends beyond current genomic methods and could reach broader patient populations.
Why now? Alongside the raise, subsidiary CORE Biomedicine Japan won a grant from the Japan Agency for Medical Research and Development (AMED), part of a competitive scheme to strengthen Japan's pharmaceutical startup ecosystem. The money will fund research and development through partnerships with Japanese hospitals, universities, and the wider biopharma community.
CORE was founded by former leaders of H3 BiomedicineDealroom has a profile for this one. Try Dealroom →.
What they're saying: "This venture financing and AMED's support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines," said co-founder and chief executive officer Dr. Ping Zhu.
Dr. Makoto Ohori, chief investment officer at UTokyo Innovation Platform, said CORE's approach tackles a challenge in cancer biology that genomics alone cannot address.
The signal: At $21 million, the round sits near the middle of comparable deals — around the 51st percentile by size. That places CORE among typical early-stage biotech raises rather than the outliers, but the pairing of private capital with state-backed AMED support signals Japan's push to build out its homegrown drug-development pipeline.
Read more: Third News
